NCT02339571 2026-03-19
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
3 trialsNCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting